|Day Low/High||19.02 / 20.25|
|52 Wk Low/High||7.56 / 23.57|
Podium Presentation at the AAHKS Annual Meeting Shows Zilretta Delivers Extended Relief Compared to Immediate-Release Steroid and Placebo
In trading on Thursday, shares of Flexion Therapeutics, Inc. touched a new 52-week high of $22.00/share.
- Magee is a seasoned pharmaceutical executive with significant experience building effective sales teams and launching products -
An update on the market and my stock of the week, TPI Composites.
Flexion (FLXN) stock closed sharply lower on Wednesday after announcing plans to raise $77 million from a stock offering.
There is some good speculative trading and metals are the place to be.
Investors eyeing a purchase of Flexion Therapeutics, Inc. stock, but tentative about paying the going market price of $15.38/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Study to Determine If Zilretta Can Avoid the Hyperglycemia that is Commonly Observed in Diabetic Patients Who Receive Immediate-Release Triamcinolone Acetonide (TCA) Injections for Knee Osteoarthritis
Podium presentation highlights results from pivotal clinical trials completed in patients with osteoarthritis (OA) of the knee